Biopharmaceutical Third Party Logistics Market - Global Forecast 2025-2032

The biopharmaceutical third-party logistics market is experiencing intensified demand for specialized, technology-enabled solutions that ensure product integrity, regulatory compliance, and operational efficiency across increasingly complex global supply chains. Senior executives are prioritizing resilient logistics networks to support the sector’s dynamic transition toward advanced biologics and personalized medicines.

Market Snapshot: Biopharmaceutical Third-Party Logistics Market

The biopharmaceutical third-party logistics market grew from USD 121.77 billion in 2024 to USD 140.03 billion in 2025 and is projected to achieve a 14.67% CAGR, reaching USD 364.23 billion by 2032. This expansion is driven by rising demand for temperature-sensitive biologics, growing regulatory requirements, and widespread adoption of digital supply chain technologies.

Scope & Segmentation

This report provides detailed analysis across the following segments and regions:

• Service Type: Distribution management, packaging and labeling (active packaging, controlled atmosphere packaging, refrigerated containers, labeling services, passive packaging), transportation (air transport, express air, standard air, rail, road, sea), warehousing (ambient, cold storage).
• Temperature Range: Ambient, chilled, monitored chilled, standard chilled, controlled room temperature, monitored controlled room temperature, standard controlled room temperature, frozen, standard frozen, ultra frozen.
• Mode of Transportation: Air freight (express, standard), rail freight, road transport (full truck load, less than truck load), sea freight (full container load, less than container load).
• End User: Biopharmaceutical manufacturers, contract manufacturing organizations, contract research organizations, diagnostic laboratories, hospitals and clinics (community hospitals, research hospitals).
• Product Type: Cell therapies (dendritic cell, stem cell), gene therapies, monoclonal antibodies, recombinant proteins, vaccines (inactivated, live attenuated).
• Packaging Type: Active packaging (refrigerated containers, temperature controlled shippers), passive packaging (insulated boxes, thermal blankets).
• Regions: Americas (United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru), Europe, Middle East & Africa (multiple European countries, UAE, Saudi Arabia, South Africa, Nigeria, Egypt, Kenya), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan).
• Key Companies: Kuehne + Nagel International AG, Deutsche Post AG, DSV Panalpina A/S, DB Schenker Logistics Germany AG & Co. KG, United Parcel Service Inc., FedEx Corporation, CEVA Logistics AG, Agility Public Warehousing Company K.S.C.P., Bolloré SE, Expeditors International of Washington, Inc.

Key Takeaways for Decision-Makers

• Specialized logistics capabilities are increasingly essential as therapies shift from conventional biologics to sensitive cell and gene treatments, necessitating investments in advanced temperature control and compliant handling.
• Integrated digital platforms—such as IoT sensors, real-time tracking, and predictive analytics—are transforming visibility and control, supporting proactive risk management and streamlined operations throughout the supply chain.
• Tightened regulations demand robust serialization, traceability, and documentation, prompting logistics providers to work closely with compliance experts to navigate evolving international standards.
• Regional variations require tailored infrastructure investments: established cold chain networks in North America contrast with rapid upgrades in Asia-Pacific and selected Middle Eastern markets.
• Strategic partnerships, including alliances with contract organizations and technology vendors, are fueling innovation and helping to mitigate risks tied to regulatory changes and market volatility.

Tariff Impact on U.S. Market Strategy

Recent U.S. tariff implementations have created substantial cost pressures across the logistics value chain. Providers are now reevaluating supplier networks, considering nearshoring, renegotiating contracts, and shifting towards multimodal transport to balance cost and reliability. These ongoing adaptations influence procurement and distribution planning for pharma companies and their partners.

Methodology & Data Sources

This report combines primary research—in-depth interviews with senior executives, supply chain leaders, and regulatory officials—with secondary data analysis from industry publications, customs records, and regulatory documents. Advanced statistical models and expert peer review underpin the accuracy and relevance of all findings.

Why This Biopharmaceutical Third-Party Logistics Market Report Matters

• Informs strategy development with actionable intelligence on digital transformation, regulatory compliance, and global expansion.
• Benchmarks leading vendors and innovation trends to support partner selection and investment decisions.
• Equips decision-makers to optimize supply chain resilience, cost management, and therapy delivery speed in an increasingly complex global landscape.

Conclusion

The biopharmaceutical third-party logistics market is advancing rapidly, placing new demands on logistics excellence, technology adoption, and collaborative strategy. Informed leadership and agile operations are key to sustaining growth and competitive advantage.

 

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.